S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Health and Healthcare

Stemline Therapeutics Files for IPO (STML)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published

Invalid Image
Stemline Therapeutics, Inc. has just filed its paperwork with the Securities and Exchange Commission that will allow it to conduct an initial public offering. The company will list is shares under the ticker “STML” on NASDAQ. The company hired Oppenheimer & Co. and JMP Securities to lead its initial public offering.

The filing noted in its own description area:

We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. We believe that we are developing the most clinically advanced pipeline of anti-CSC therapeutics and that we hold a broad portfolio of CSC-focused intellectual property, establishing us as a leader in the CSC field.

No financial terms were disclosed other than this offering will be for up to $50 million. The company has three uses for the proceeds in the offering:

  • It plans to advance SL-401 into a randomized Phase 2b clinical trial to treat adult AML patients as a third-line treatment.
  • It plans to advance SL-701 into a pivotal Phase 2b clinical trial to treat pediatric patients with newly diagnosed BSG. It also plans to initiate a randomized Phase 2b clinical trial of SL-701 in adult second-line GBM.
  • The remaining proceeds will be used to fund working capital, capital expenditures and other general corporate purposes.

JON C. OGG

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
Michael Williams |

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month
Michael Williams |

The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month

Continue Reading

Visterra Readies for IPO
Chris Lange |

Visterra Readies for IPO

Visterra has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Akebia Plans to Raise Capital in Most Recent Proposed Offering
Chris Lange |

Akebia Plans to Raise Capital in Most Recent Proposed Offering

Akebia Therapeutics plans on raising capital, according to its most recent proposed public offering.

Poseida Therapeutics Gears Up for IPO
Chris Lange |

Poseida Therapeutics Gears Up for IPO

Clinical-stage biopharmaceutical company Poseida Therapeutics has filed with the SEC regarding its initial public offering.

Chris Lange |

DBV Technologies Files for IPO, Sort Of

DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering

Chris Lange |

Nabriva Files for IPO

Nabriva Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Chris Lange |

Civitas Therpeutics Files for IPO

Civitas Therapeutics filed with the U.S. Securities and Exchange Commission for an initial public offering.

Chris Lange |

vTv Therapeutics Sets Expected Price Range for IPO

vTv Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Chris Lange |

Atara Biotherapeutics Files for IPO

Atara Biotherapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

BioXel Gears Up for IPO
Chris Lange |

BioXel Gears Up for IPO

Clinical-stage biopharmaceutical company BioXel Therapeutics has filed with the SEC regarding its initial public offering.

Top Gaining Stocks

Airbnb
ABNB • Vol: 15,913,532
Microchip Technology
MCHP • Vol: 19,139,274
Palantir
PLTR • Vol: 77,244,625
Moderna
MRNA • Vol: 6,820,582
Axon Enterprise
AXON • Vol: 1,591,869

Top Losing Stocks

Trade Desk
TTD • Vol: 133,458,224
Coterra Energy
CTRA • Vol: 73,319,495
Akamai
AKAM • Vol: 8,143,961
Zoetis
ZTS • Vol: 12,784,553
ResMed
RMD • Vol: 3,810,438